Genomic drug developer Tessera Therapeutics raised $230m in a round co-led by SoftBank Vision Fund 2 as it works on its gene writing technology.

Monogenic disease therapy developer Lexeo Therapeutics has publicly launched with financing from backers including Lundbeckfonden Ventures.

Lilly Asia Ventures has led a $23.2m round for the digital diagnostics technology developer, investing alongside new and existing backers.

Sanofi and Mass General Brigham contributed to a round that pushed the immunotherapy developer's total funding to nearly $60m.

Cambrian Biopharma returned to back the immunotherapy developer's series B round, following its series A three months ago.

GV and Nextech contributed to a series B round that boosted the affordable pharmaceutical developer's overall funding to $750m.

Hepalink will exit the immune and inflammatory disease drug developer in an acquisition that could reach $1.45bn in size.

Lilly Asia Ventures, a regional corporate venturing subsidiary of pharmaceutical firm Eli Lilly, reinvested in a round set to accelerate development of Abbisko's cancer-focused drug candidates.

GV, MRL Ventures Fund and WuXi Healthcare Ventures participated in a series B round that lifted the small molecule therapy developer's overall funding to $120m.

Takeda Digital Ventures, Humana, McKesson Ventures and dRx Capital backed the online pharmacy platform developer's series B round.